Nontoxic goiter-diffuse or nodular.
Maloof F, Wang CA, Vickery AL Jr.
Med Clin North Am. 1975 Sep;59(5):1221-32. doi: 10.1016/s0025-7125(16)31970-8.
Goiter in adolescents.
Foley TP Jr.
Endocrinol Metab Clin North Am. 1993 Sep;22(3):593-606.
Prediction factors for the risk of diffuse non-toxic goiter development in type 2 diabetic patients.
Musiienko V, Sverstiuk A, Lepyavko A, Mazur L, Danchak S, Lisnianska N.
Pol Merkur Lekarski. 2022 Apr 19;50(296):94-98.
[From diffuse goiter to nodular goiter].
Derwahl M.
Internist (Berl). 1998 Jun;39(6):577-83. doi: 10.1007/s001080050214.
Thyroid-related ophthalmology.
Zobian J, Maus M.
Curr Opin Ophthalmol. 1998 Dec;9(6):105-10. doi: 10.1097/00055735-199812000-00019.
Clinical-laboratory and ultrasound parallels of changes in the liver and thyroid gland in diffuse toxic goiter.
Lavruk KZ, Dudiy PF, Skrypnyk NV, Mishchuk VH, Vytvytskiy ZY.
J Med Life. 2022 Jan;15(1):78-88. doi: 10.25122/jml-2021-0291.
Diagnostic dilemma. The goiter.
Alter CA, Moshang T Jr.
Pediatr Clin North Am. 1991 Jun;38(3):567-78. doi: 10.1016/s0031-3955(16)38118-4.
Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters.
Knobel M.
J Endocrinol Invest. 2016 Apr;39(4):357-73. doi: 10.1007/s40618-015-0391-7. Epub 2015 Sep 21.
[Diffuse lipomatosis in amyloidotic goiter].
Carballo L, Dardik D, Besada C.
Medicina (B Aires). 2015;75(6):419.
[Peculiarities of formation, clinical presentations and therapy of diffuse nontoxic goiter of children].
Byriak VN, Murashko ES.
Lik Sprava. 2012 Apr-Jun;(3-4):31-5.
